Progress Of Bayer’s Postmarket Essure Study ‘Inadequate’ Says FDA
Nearly half of the women with the device are no longer participating
Executive Summary
The US FDA labelled the progress of Bayer’s 522 postmarket study of its Essure birth control device, which was pulled off the market in 2018, as “inadequate” due to significant numbers of women dropping out.
You may also be interested in...
News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals
This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.
Study Progress Updated To ‘Ongoing’: FDA Publishes Interim Report Three Years Into Essure Study
In a report on Bayer’s postmarket study of Essure, the FDA says Bayer’s study is back on track with its five-year plan.
Essure-Related Complications Still A Problem, Latest FDA Data Show
Interim data from two ongoing studies show more women have had the Essure birth control device removed while many are still experiencing adverse events, such as pain and bleeding.